MEGATOPE
LOE Approachingiodinated i-131 albumin
BLAINJECTIONINJECTABLE
Approved
Feb 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
MEGATOPE (iodinated i-131 albumin) is clinical pharmacology following intravenous injection, iodinated i 131 albumin is distributed throughout the intravascular pool within 10 minutes; extravascular distribution takes place more slowly. Approved for plasma volumes. First approved in 1976.
Drug data last refreshed 5h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEGATOPE is an iodinated I-131 albumin injectable diagnostic agent used to measure plasma volume by tracing radioactive distribution through intravascular and extravascular spaces. Following IV injection, it distributes throughout the intravascular pool within 10 minutes and reaches equilibrium in extravascular tissues over 2-4 days, with a biologic half-life of approximately 14 days in normal individuals.
LOE Approaching
This legacy diagnostic product is approaching loss of exclusivity with minimal linked career opportunities and likely declining commercial activity.
Mechanism of Action
CLINICAL PHARMACOLOGY Following intravenous injection, iodinated I 131 albumin is distributed throughout the intravascular pool within 10 minutes; extravascular distribution takes place more slowly. Iodinated I 131 albumin also can be detected in the lymph and in certain body tissues within 10…
Indications (1)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.